Ivabradine
Solution · trading as Corlanor
To Be Discontinued Active (discontinuing) — Day 51
FDA shortage record
- Substance
- Ivabradine
- Brand name
- Corlanor
- Manufacturers / suppliers
-
- Amgen Inc
- Amgen Inc.
- Dosage form
- Solution
- Presentation
- Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)
- Route(s)
- ORAL
- Therapeutic category
- Cardiovascular
- Package NDC
55513-813-28- Initially posted
- 03/24/2026
- Days on shortage list
- 51
- Discontinued
- 01/01/2026
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 2 records for Ivabradine
Why this shortage matters
Cardiovascular drugs manage heart failure, arrhythmias, hypertension, and coronary artery disease. Shortages can disrupt stable long-term therapy or create gaps in acute care where dosing consistency is essential to preventing cardiac events.
FDA therapeutic class: Cardiovascular
Reason and context
Discontinuation of the manufacture of the drug product
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 1-800-772-6436.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
92018a65-38f6-45f7-91d4-a34921b81d0d). - FDA UNII identifier:
TP19837BZK. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.